Clinical Trial Update: Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating the safety and preliminary activity of nivolumab combined with vorolanib in patients with refractory thoracic tumors, including thym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Thymic Carcinoma

Drugs mentioned

• Opdivo (nivolumab) (nivolumab)
• Vorolanib (vorolanib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Thymic Carcinoma, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-08